V1-69 Antiviral Broadly Neutralizing Antibodies: Genetics, Structures, and Relevance to Rational Vaccine Design

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2019 Mar 19

PMID 30884330

Citations 81

Authors

Fang Chen

Netanel Tzarum

Ian A Wilson

Mansun Law

Affiliations

Soon will be listed here.

Abstract

Broadly neutralizing antibodies (bnAbs) are potential therapeutic molecules and valuable tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody responses to conserved epitopes can be highly convergent at the molecular level. Human antibodies targeting a number of viral antigens have often been found to utilize a restricted set of immunoglobulin germline genes in different individuals. Here we review recent knowledge on V1-69-encoded antibodies in antiviral responses to influenza virus, HCV, and HIV-1. These antibodies share common genetic and structural features, and often develop neutralizing activity against a broad spectrum of viral strains. Understanding the genetic and structural characteristics of such antibodies and the target epitopes should help advance novel strategies to elicit bnAbs through vaccination.

Citing Articles

How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza.

Steventon R, Stolle L, Thompson C Antibodies (Basel). 2025; 14(1.

PMID: 39846612 PMC: 11755579. DOI: 10.3390/antib14010004.

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV.

Suryadevara N, Kose N, Bangaru S, Binshtein E, Munt J, Martinez D J Clin Invest. 2024; 135(3).

PMID: 39589795 PMC: 11785922. DOI: 10.1172/JCI178880.

Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem.

Ataca S, Sangesland M, de Paiva Froes Rocha R, Torrents de la Pena A, Ronsard L, Boyoglu-Barnum S Cell Rep. 2024; 43(12):114990.

PMID: 39580804 PMC: 11672684. DOI: 10.1016/j.celrep.2024.114990.

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.

Piepenbrink M, Khalil A, Chang A, Mostafa A, Basu M, Sarkar S Npj Viruses. 2024; 2(1):55.

PMID: 39553825 PMC: 11564104. DOI: 10.1038/s44298-024-00063-z.

Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination.

Raju N, Kramer K, Cavallaro M, Diotti R, Shiakolas A, Campos Mota Y J Immunol. 2024; 213(11):1605-1619.

PMID: 39441352 PMC: 11573632. DOI: 10.4049/jimmunol.2400326.

References

Erbelding E, Post D, Stemmy E, Roberts P, Augustine A, Ferguson S . A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018; 218(3):347-354. PMC: 6279170. DOI: 10.1093/infdis/jiy103. View

Bruni R, Costantino A, Tritarelli E, Marcantonio C, Ciccozzi M, Rapicetta M . A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process. BMC Struct Biol. 2009; 9:48. PMC: 2732612. DOI: 10.1186/1472-6807-9-48. View

Lefranc M . Immunoglobulins: 25 years of immunoinformatics and IMGT-ONTOLOGY. Biomolecules. 2014; 4(4):1102-39. PMC: 4279172. DOI: 10.3390/biom4041102. View

Lingwood D, McTamney P, Yassine H, Whittle J, Guo X, Boyington J . Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature. 2012; 489(7417):566-70. PMC: 7095019. DOI: 10.1038/nature11371. View

Doria-Rose N, Schramm C, Gorman J, Moore P, Bhiman J, DeKosky B . Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509(7498):55-62. PMC: 4395007. DOI: 10.1038/nature13036. View

Euler Z, van Gils M, Boeser-Nunnink B, Schuitemaker H, van Manen D . Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. PLoS One. 2013; 8(1):e54684. PMC: 3553002. DOI: 10.1371/journal.pone.0054684. View

Williams W, Liao H, Moody M, Kepler T, Alam S, Gao F . HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015; 349(6249):aab1253. PMC: 4562404. DOI: 10.1126/science.aab1253. View

Kwong P, Mascola J . Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412-25. PMC: 4706166. DOI: 10.1016/j.immuni.2012.08.012. View

Schramm C, Douek D . Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design. Front Immunol. 2018; 9:1876. PMC: 6102386. DOI: 10.3389/fimmu.2018.01876. View

10.

Jardine J, Julien J, Menis S, Ota T, Kalyuzhniy O, McGuire A . Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013; 340(6133):711-6. PMC: 3689846. DOI: 10.1126/science.1234150. View

11.

Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall D . Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532. PMC: 3184076. DOI: 10.1371/journal.pone.0023532. View

12.

Fox A, Quinn K, Subbarao K . Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine. Drugs. 2018; 78(13):1297-1308. DOI: 10.1007/s40265-018-0958-7. View

13.

Moustafa R, Haddad J, Linna L, Hanoulle X, Descamps V, Mesalam A . Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. J Virol. 2018; 92(20). PMC: 6158422. DOI: 10.1128/JVI.00939-18. View

14.

Luftig M, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G . Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol. 2006; 13(8):740-7. DOI: 10.1038/nsmb1127. View

15.

Henry Dunand C, Wilson P . Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1676). PMC: 4528415. DOI: 10.1098/rstb.2014.0238. View

16.

MacLeod D, Choi N, Briney B, Garces F, Ver L, Landais E . Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity. 2016; 44(5):1215-26. PMC: 5003182. DOI: 10.1016/j.immuni.2016.04.016. View

17.

Miller M, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H . A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A. 2005; 102(41):14759-64. PMC: 1253587. DOI: 10.1073/pnas.0506927102. View

18.

Throsby M, van den Brink E, Jongeneelen M, Poon L, Alard P, Cornelissen L . Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008; 3(12):e3942. PMC: 2596486. DOI: 10.1371/journal.pone.0003942. View

19.

Whittle J, Zhang R, Khurana S, King L, Manischewitz J, Golding H . Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 2011; 108(34):14216-21. PMC: 3161572. DOI: 10.1073/pnas.1111497108. View

20.

Sabin C, Corti D, Buzon V, Seaman M, Hulsik D, Hinz A . Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 2010; 6(11):e1001195. PMC: 2987821. DOI: 10.1371/journal.ppat.1001195. View